Q3 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Stock analysts at HC Wainwright decreased their Q3 2025 earnings per share (EPS) estimates for Nuvation Bio in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.16) for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.73 million for the quarter.

Several other research firms have also recently issued reports on NUVB. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Wedbush restated an “outperform” rating and set a $5.00 price target on shares of Nuvation Bio in a research report on Monday, January 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.20.

Nuvation Bio Trading Down 1.8 %

Shares of NYSE NUVB opened at $2.46 on Monday. Nuvation Bio has a 12-month low of $1.52 and a 12-month high of $4.16. The company has a market cap of $826.28 million, a PE ratio of -1.13 and a beta of 1.47. The stock has a 50 day simple moving average of $2.73 and a 200-day simple moving average of $2.78.

Institutional Trading of Nuvation Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in NUVB. State Street Corp increased its stake in Nuvation Bio by 4.8% in the 3rd quarter. State Street Corp now owns 4,166,441 shares of the company’s stock worth $9,541,000 after purchasing an additional 191,031 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Nuvation Bio by 83.3% in the third quarter. Wellington Management Group LLP now owns 623,973 shares of the company’s stock worth $1,429,000 after buying an additional 283,642 shares during the period. Geode Capital Management LLC increased its position in shares of Nuvation Bio by 5.1% in the third quarter. Geode Capital Management LLC now owns 4,028,692 shares of the company’s stock worth $9,227,000 after acquiring an additional 196,247 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Nuvation Bio by 415.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock valued at $2,975,000 after acquiring an additional 820,669 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Nuvation Bio in the 3rd quarter valued at approximately $634,000. 61.67% of the stock is owned by institutional investors and hedge funds.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.